Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
12
NVCR Quote, Financials, Valuation and Earnings
Last price:
$11.35
Seasonality move
:
6.56%
Day range:
$11.11 - $11.47
52-week range:
$9.82 - $22.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.96x
P/B ratio:
3.73x
Volume:
1.3M
Avg. volume:
2.1M
1-year change:
-47.53%
Market cap:
$1.3B
Revenue:
$605.2M
EPS (TTM):
-$1.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$173.4M | -$0.41 | -2.7% | -68.7% | $25.21 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
ARAY
Accuray, Inc.
|
$135.2M | $0.03 | -1.19% | -296.83% | $2.53 |
|
ATRC
AtriCure, Inc.
|
$139.8M | -$0.04 | 12.89% | -57.61% | $48.78 |
|
LIVN
LivaNova Plc
|
$354.3M | $0.81 | 6.94% | -20.28% | $73.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$11.36 | $25.21 | $1.3B | -- | $0.00 | 0% | 1.96x |
|
ABT
Abbott Laboratories
|
$112.21 | $133.39 | $195.1B | 30.30x | $0.63 | 2.14% | 4.43x |
|
ARAY
Accuray, Inc.
|
$0.54 | $2.53 | $60.7M | 149.00x | $0.00 | 0% | 0.14x |
|
ATRC
AtriCure, Inc.
|
$32.58 | $48.78 | $1.6B | -- | $0.00 | 0% | 2.91x |
|
LIVN
LivaNova Plc
|
$68.42 | $73.00 | $3.7B | 38.16x | $0.00 | 0% | 2.78x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.28 | $5.50 | $37.8M | -- | $0.00 | 0% | 4.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
70.04% | 0.751 | 55.15% | 1.44x |
|
ABT
Abbott Laboratories
|
20.25% | 0.141 | -- | 1.12x |
|
ARAY
Accuray, Inc.
|
76.53% | 1.394 | 186.42% | 0.52x |
|
ATRC
AtriCure, Inc.
|
13.46% | 1.617 | 3.89% | 2.88x |
|
LIVN
LivaNova Plc
|
29.6% | 1.643 | 17.01% | 1.05x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | -$21.6M |
|
ATRC
AtriCure, Inc.
|
$104.6M | $3.5M | -2.09% | -2.44% | 2.49% | $18.4M |
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
NovoCure Ltd. vs. Competitors
-
Which has Higher Returns NVCR or ABT?
Abbott Laboratories has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 15.5%. NovoCure Ltd.'s return on equity of -50.08% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About NVCR or ABT?
NovoCure Ltd. has a consensus price target of $25.21, signalling upside risk potential of 121.96%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 18.88%. Given that NovoCure Ltd. has higher upside potential than Abbott Laboratories, analysts believe NovoCure Ltd. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 ABTAbbott Laboratories16 7 0 -
Is NVCR or ABT More Risky?
NovoCure Ltd. has a beta of 0.728, which suggesting that the stock is 27.187% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.
-
Which is a Better Dividend Stock NVCR or ABT?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.14% to investors and pays a quarterly dividend of $0.63 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVCR or ABT?
NovoCure Ltd. quarterly revenues are $167.2M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. NovoCure Ltd.'s net income of -$37.3M is lower than Abbott Laboratories's net income of $1.8B. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 30.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 1.96x versus 4.43x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.1.96x -- $167.2M -$37.3M ABTAbbott Laboratories4.43x 30.30x $11.5B $1.8B
-
Which has Higher Returns NVCR or ARAY?
Accuray, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -13.47%. NovoCure Ltd.'s return on equity of -50.08% beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About NVCR or ARAY?
NovoCure Ltd. has a consensus price target of $25.21, signalling upside risk potential of 121.96%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 371.7%. Given that Accuray, Inc. has higher upside potential than NovoCure Ltd., analysts believe Accuray, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 ARAYAccuray, Inc.2 0 0 -
Is NVCR or ARAY More Risky?
NovoCure Ltd. has a beta of 0.728, which suggesting that the stock is 27.187% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.
-
Which is a Better Dividend Stock NVCR or ARAY?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or ARAY?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Accuray, Inc. quarterly revenues of $102.2M. NovoCure Ltd.'s net income of -$37.3M is lower than Accuray, Inc.'s net income of -$13.8M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 1.96x versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.1.96x -- $167.2M -$37.3M ARAYAccuray, Inc.0.14x 149.00x $102.2M -$13.8M
-
Which has Higher Returns NVCR or ATRC?
AtriCure, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 1.25%. NovoCure Ltd.'s return on equity of -50.08% beat AtriCure, Inc.'s return on equity of -2.44%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B ATRCAtriCure, Inc.74.43% $0.04 $568.4M -
What do Analysts Say About NVCR or ATRC?
NovoCure Ltd. has a consensus price target of $25.21, signalling upside risk potential of 121.96%. On the other hand AtriCure, Inc. has an analysts' consensus of $48.78 which suggests that it could grow by 49.72%. Given that NovoCure Ltd. has higher upside potential than AtriCure, Inc., analysts believe NovoCure Ltd. is more attractive than AtriCure, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 ATRCAtriCure, Inc.4 2 0 -
Is NVCR or ATRC More Risky?
NovoCure Ltd. has a beta of 0.728, which suggesting that the stock is 27.187% less volatile than S&P 500. In comparison AtriCure, Inc. has a beta of 1.415, suggesting its more volatile than the S&P 500 by 41.514%.
-
Which is a Better Dividend Stock NVCR or ATRC?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AtriCure, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. AtriCure, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or ATRC?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than AtriCure, Inc. quarterly revenues of $140.5M. NovoCure Ltd.'s net income of -$37.3M is lower than AtriCure, Inc.'s net income of $1.8M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while AtriCure, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 1.96x versus 2.91x for AtriCure, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.1.96x -- $167.2M -$37.3M ATRCAtriCure, Inc.2.91x -- $140.5M $1.8M
-
Which has Higher Returns NVCR or LIVN?
LivaNova Plc has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 7.49%. NovoCure Ltd.'s return on equity of -50.08% beat LivaNova Plc's return on equity of -18.29%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B LIVNLivaNova Plc68.44% $0.49 $1.6B -
What do Analysts Say About NVCR or LIVN?
NovoCure Ltd. has a consensus price target of $25.21, signalling upside risk potential of 121.96%. On the other hand LivaNova Plc has an analysts' consensus of $73.00 which suggests that it could grow by 6.69%. Given that NovoCure Ltd. has higher upside potential than LivaNova Plc, analysts believe NovoCure Ltd. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 LIVNLivaNova Plc6 2 0 -
Is NVCR or LIVN More Risky?
NovoCure Ltd. has a beta of 0.728, which suggesting that the stock is 27.187% less volatile than S&P 500. In comparison LivaNova Plc has a beta of 0.967, suggesting its less volatile than the S&P 500 by 3.292%.
-
Which is a Better Dividend Stock NVCR or LIVN?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LivaNova Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. LivaNova Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or LIVN?
NovoCure Ltd. quarterly revenues are $167.2M, which are smaller than LivaNova Plc quarterly revenues of $357.8M. NovoCure Ltd.'s net income of -$37.3M is lower than LivaNova Plc's net income of $26.8M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while LivaNova Plc's PE ratio is 38.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 1.96x versus 2.78x for LivaNova Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.1.96x -- $167.2M -$37.3M LIVNLivaNova Plc2.78x 38.16x $357.8M $26.8M
-
Which has Higher Returns NVCR or PSTV?
Plus Therapeutics, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -316.61%. NovoCure Ltd.'s return on equity of -50.08% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About NVCR or PSTV?
NovoCure Ltd. has a consensus price target of $25.21, signalling upside risk potential of 121.96%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than NovoCure Ltd., analysts believe Plus Therapeutics, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is NVCR or PSTV More Risky?
NovoCure Ltd. has a beta of 0.728, which suggesting that the stock is 27.187% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock NVCR or PSTV?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or PSTV?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. NovoCure Ltd.'s net income of -$37.3M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 1.96x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.1.96x -- $167.2M -$37.3M PSTVPlus Therapeutics, Inc.4.41x -- $1.4M -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
